Daniel Gil-Alós

Dr. Daniel Gil-Alós

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2025 in Blood
Verified
Journal Article
Open access
CKCorynn Kasap
Corynn Kasap
AIAdila Izgutdina
Adila Izgutdina
BPBonell Patiño-Escobar
Bonell Patiño-Escobar
AKAmrik Singh Kang
Amrik Singh Kang
NCNikhil Chilakapati
Nikhil Chilakapati
AWArun P. Wiita
Arun P. Wiita
Despite the success of BCMA-targeting CAR-Ts in multiple myeloma, patients with high-risk cytogenetic features still relapse most quickly and are in urgent need of additional therapeutic options. Here, we identify CD70, widely recognized as a favorable immunotherapy target in other cancers, as a specifically upregulated cell surface antigen in high-risk myeloma tumors. We use a structure-guided design to define a CD27-based anti-CD70 CAR-T design that outperforms all tested scFv-based CARs, leading to >80-fold improved CAR-T expansion in vivo. Epigenetic analysis via machine learning predicts key transcription factors and transcriptional networks driving CD70 upregulation in high-risk myeloma. Dual-targeting CAR-Ts against either CD70 or BCMA demonstrate a potential strategy to avoid antigen escape-mediated resistance. Together, these findings support the promise of targeting CD70 with optimized CAR-Ts in myeloma as well as future clinical translation of this approach.

28 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
RPRosa Pello
Rosa Pello
MPMaria de los Angeles Iglesias de la Puente
Maria de los Angeles Iglesias de la Puente
RVRaul Vidal
Raul Vidal
RMRaúl Mateos
Raúl Mateos
MPMarta Outón Porras
Marta Outón Porras
MCM TERESA CEDENA
M TERESA CEDENA
Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.

20 November 2025 in Cytotherapy
Verified
Journal Article
Open access
LCLaura Córdoba-Espejo
Laura Córdoba-Espejo
LSLaura Sánchez-Vega
Laura Sánchez-Vega
AGAlmudena García-Ortiz
Almudena García-Ortiz
ECEva Castellano
Eva Castellano
RORaquel Oliva
Raquel Oliva
Joaquin Martinez-LopezJoaquin Martinez-Lopez
Joaquin Martinez-Lopez
Chimeric Antigen Receptor (CAR)-T cell therapy has shown promising results in hematological malignancies but faces limitations such as the need for autologous products or additional modifications of allogeneic T cell sources to prevent graft-versus-host disease (GvHD). In acute myeloid leukemia (AML), its application is particularly challenging due to antigen overlap between malignant cells and healthy hematopoietic stem cells, leading to severe and often fatal toxicities due to on-target, off-tumor effect. Natural killer (NK) cells offer a promising alternative for CAR therapy, as they are well tolerated and exert antitumor activity beyond CAR-mediated mechanisms. Peripheral blood (PB) is an accessible NK cell source with a relatively high proportion of mature NK cells; however, generating clinically relevant numbers of highly transduced PB-derived CAR-NK cells in closed systems remains challenging, and production protocols need optimization. Here, we evaluated different manufacturing strategies to generate NKG2D CAR-NK cells from PB in the CliniMACS Prodigy closed platform. We established an optimized protocol that achieved enhanced transduction efficiency, yielding high numbers of CAR+ cells. The final product met good manufacturing practice (GMP)-aligned safety and sterility requirements, displayed superior in vitro cytotoxicity against AML cell lines compared to the same product manufactured in the preclinical setting, and delayed tumor progression in an AML xenografted mouse model without cytokine support. This standardized, GMP-compliant protocol provides a robust platform for producing PB-derived CAR-NK cell therapies in a closed platform, advancing their clinical translation.

30 October 2026 in Blood Advances
Verified
Journal Article
Open access
AMAnna Martín-Carrizosa
Anna Martín-Carrizosa
CGCristina García-Herce
Cristina García-Herce
DVDavid Quintela Vilchez
David Quintela Vilchez
JHJuan Carlos Caballero Hernáez
Juan Carlos Caballero Hernáez
RMRocio Figueroa Mora
Rocio Figueroa Mora
PAPau Abrisqueta
Pau Abrisqueta